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Abstract 
 
This article updates the guidance published in 2015 for authors submitting papers to British Journal 
of Pharmacology (BJP) (Curtis et al., 2015) and is intended to provide the rubric for peer review. 
Thus, it is directed towards authors, reviewers and editors. Explanations for many of the 
requirements were outlined previously and are not restated here. The new guidelines are intended 
to replace those published previously.  The guidelines have been simplified for ease of 
understanding by authors, to make it more straightforward for peer reviewers to check compliance, 
and to facilitate the curation of the journal’s efforts to improve standards. 
 
Introduction 
 
The aim of this update is to: 
 share and apply lessons learnt during the 2 years since the implementation of our guidelines  
 update aspects of design and analysis where our views have changed/advanced since 2015  
 include advice and guidelines on additional areas of design and analysis pertinent to 
pharmacology research but not discussed in the previous version 
 make the journal requirements clearer and easier to curate.  
 
With respect to this final point, the two key changes/additions are a simplified list of requirements 
for authors, and a flow chart explaining how peer review may be accomplished efficiently. The 
latter is focused on addressing issues that have been journal requirements since 2015, but which 
internal audit has revealed are not being routinely addressed by authors and are being missed 
during the peer review process. This issue of ‘non-compliance’ is not unique to BJP and is a 
phenomenon experienced by many other journals. Indeed, Nature recently reported that when 
guidelines are introduced, ‘author compliance can be an issue’ (anonymous 2017).  
 
Our intention is to improve our guidelines to make it clearer to authors what we require, easier for 
peer review to manage and easier for the British Pharmacological Society (BPS), which owns the 
journal, to curate. In doing this, we facilitate one of our key aims which is to support the improved 
reporting and ‘transparency’ of experimental work. This article also provides figures to illustrate key 
aspects of good and inappropriate practice in data acquisition and processing in order to further 
clarify what is acceptable and unacceptable to BJP.  
 
We focus on issues that, in the experience of the Senior Editorial team, continue to be problematic 
(e.g. normalisation, transformation and inappropriate use of parametric statistics). Additionally, we 
provide new guidance on certain more nuanced issues, including the handling of outliers in 
datasets. We note, finally, that this new guidance is entirely focused on design and analysis. 
Previous attempts in our journal have combined requirements for design and analysis with other 
equally important, but distinct, issues concerning the use of animals and experimental ethics (e.g. 
ARRIVE). In hindsight, we feel that this combination has been detrimental and has contributed to a 
lack of clarity, which may have resulted in the inadequate compliance that we have found from our 
audits of research papers published in BJP in 2016 and 2017. Guidance on the publication in BJP of 
ethical animal experimentation and ARRIVE are published elsewhere (McGrath and Lilley 2015), and 
will be updated in 2018. 
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In order to achieve our objectives the BJP requires that every paper should contain a design and 
analysis sub-section within the Methods. 
 
Key points of the updated guidance 
 
1. Group sizes should be sufficient to permit any statistical analysis to be meaningful. At the 
present time, BJP has set 5 as the minimum “n” required for datasets subjected to statistical 
analysis. Inclusion of datasets with a smaller group size (without statistical analysis) is 
permissible but only if carefully justified (e.g. shortage of sample availability). Such data should 
be labelled as ‘exploratory’ or ‘preliminary’, and should constitute only a small proportion of the 
data in the paper. We strongly advise investigators to undertake power analysis and then 
increase the calculated minimum group size by at least 50% (explained below). Group size is the 
number of independent variables, so one sample run 5 times is n=1, not n=5. We note that it is 
common for authors to run 3 samples for instance in quintuplicate, then analyse the data, with 
statistical analysis, as if it were n=15 rather than n=3. This is not acceptable for publication in 
BJP. 
2. Studies should be designed to generate groups of equal size, using randomisation and blinded 
analysis where possible (with a credible justification if this is not possible). Even a well-designed 
study may give rise to unequal group sizes owing to loss of animals/samples etc. due, for 
instance, to technical failure. If the latter has occurred, this must be explained in the Results. 
Clear statements on the use of randomisation, blinding and establishment of a priori equal 
group sizes (and whether and how any lost values were replaced) must be provided in Methods. 
3. It is important to emphasise that after ANOVA, post hoc tests may be run only if F achieves the 
necessary level of statistical significance (i.e. P<0.05) and there is no significant variance 
inhomogeneity. Adherence must be stated in the Methods (‘data were analysed by ANOVA 
followed by Tukey’s test’ is not sufficient). If these criteria are not met, a post hoc test should 
not be run (even if the software permits this, which it may).  
4. The Methods should explain the reason for any data normalisation (which means the correction 
of test values to baseline or control group values). Approaches used to reduce unwanted 
sources of variation, or to transform log-normal data to normal (Gaussian) is encouraged, but 
the details and reasons must be explained in Methods. Such transformations of the 
experimental data can affect the appropriateness of the chosen statistical method. For example, 
normalisation to matched controls will generate a control mean of 1 and no s.e.mean, meaning 
that parametric tests (ANOVA, etc.) cannot be used (only non-parametric analysis is acceptable). 
Any dataset where one group has no s.e.mean (common in western blot analysis) must be 
analysed by non-parametric statistics. Following data transformation, the Y axis is often labelled 
incorrectly (it should be ‘fold matched control values’, or ‘fold mean of the controls’, and not 
‘fold control’).  
5. When comparing groups, a level of probability (P) deemed to constitute the threshold for 
statistical significance (typically in pharmacology this is P<0.05) should be defined in Methods, 
and not varied later in Results (by presentation of multiple levels of significance). 
6. Outliers are data values that digress from the central tendency. A range of issues may need to 
be considered before an investigator can decide how to deal with outliers. It is possible to 
define an outlier in a control population, but only if the control group has been generated 
numerous times previously so that a large number of control data are available for inspection. 
Outliers should therefore be included in data analysis and presentation unless a predefined and 
defensible set of exclusion criteria can be generated and applied.  
5 
 
The peer review process  
 
We expect BJP papers to be written in such a way that the basic requirements of design and 
analysis are described clearly by authors, and can be checked in peer review. To improve this 
process, we have prepared a summary flow chart of how peer reviewers may quickly triage the key 
areas and check for compliance with BJP’s core requirements. At the same time this flow chart 
explains to authors what BJP expects from them. The triage scheme (Figure 1) should be used by 
authors and those involved in peer review to complement the updated guidance. 
 
 
Figure 1. This flow chart describes how triage of the design and analysis aspects of a paper may be checked 
by authors and by peer reviewers. 
 
 
 
Areas of particular concern that require renewed vigilance 
 
Many of the key issues in the flowchart (above) will be simple to address. Methods must make 
statements about the items listed above (Figure 1). In studies that do not comply with our 
requirements, examination of figure legends generally reveals unequal group sizes, statistical 
analysis often applied to group sizes of n<5 and use of inappropriate application of specific 
statistical tests. Together, these render a paper fundamentally flawed with respect to BJP guidance. 
We accept that there are instances during an experiment where a sample may be lost due to a 
technical issue, or where blinding the data analysis was not possible owing to a very large i.e. 
obvious, drug effect. In such scenarios authors can and should easily explain why their study falls 
short in these aspects, and we expect peer reviewers to accept a good explanation. Indeed, we also 
encourage the inclusion of pilot data (that may or may not be blinded, randomized or fit for 
statistical analysis) so long as it is clearly identified as such. In view of this we conducted an audit of 
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the general compliance with our guidance introduced in 2015. Table 1 illustrates it has not 
succeeded as we had hoped. 
 
 
 
Below we discuss specific issues illustrated in Table 1. 
 
Parametric versus non-parametric 
 
One important issue concerns normalisation and the generation of ‘normal’ (Gaussian) data 
necessary for the application of statistics that depend upon a Gaussian distribution. Figure 2, as an 
example, shows two different acceptable ways of analysing and presenting data that, for reasons 
the author should explain, are normalised to control (a common procedure in western blot analysis 
and electrophysiology studies). It is interesting, and not well recognised, that the data 
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normalisation approach shown in the right-hand part of the figure is not actually a true 
normalisation and is, in fact, simply a rescaling of the Y axis of the raw data (see legend).  The 
important difference between the two, however, is that the control on the right-hand side has a 
standard error whilst the control on the left-hand side does not.  Both are acceptable forms of data 
presentation for BJP, however the statistical tests that should be applied are different. 
 
 
 
 
 
Figure 2. Individual data points (circles), mean values (x) and s.e.mean values are shown. On the left are two 
datasets derived from an analysis (e.g. western blotting) where each drug experiment has a matched control. 
Each drug value is normalised to each matched control value. This means that the control mean is 1, and 
there is no variance in the control group (s.e.mean is zero). The correct way to analyse these data is using a 
non-parametric statistical test, and the correct label for the Y axis is ‘fold matched control’. Because analysis 
is non-parametric, it is misleading to show the parameter s.e.mean. In the figure on the right, each control 
and each drug value has been ‘normalised’ to the mean value of the control group (mean values shown as x). 
In other words, each raw value has been divided by the value of the mean of the control values. This 
generates a dataset that can be analysed by parametric statistics (provided the variance is similar in the two 
groups – a t test may falsely identify a nonsignificant difference if the two s.e.mean values differ greatly – 
see Figure 3) and, if so, it is appropriate to show the s.e.mean (error bars in the figure). However, there is 
actually no benefit in making this transformation since the ratio between each mean and each s.e.mean is 
the same as the equivalent ratios for the raw data. In other words, this ‘transformation’ is identical to a 
relabelling or rescaling of the Y axis from the absolute raw values to new values for which the control mean 
value is relabelled as ‘1’. This has no effect on the ability of the parametric statistical test to detect a 
significant difference. However, readers have a tendency to make ‘eyeball’ comparisons between normalised 
datasets in the same paper or indeed from one paper to the next, and this may lead to false inferences. 
Thus, use of either the normalisation shown in the left-hand figure, or presentation of the raw data (in units 
that may be arbitrary if this is the case) is preferred, although we acknowledge that for quantitative PCR the 
‘transformation’ depicted in the right-hand panel represents common practice at the present time. We also 
remind authors to ensure that whatever normalisation is chosen, the Y axis is labelled correctly (fold control 
is not correct) and the appropriate type of statistical test is used. 
 
Data transformation is another important issue for transparency. Our audit has revealed two key 
issues: 
 The first is that data that are not normally distributed must not be subjected to parametric 
statistical analysis (t tests, ANOVA and post hoc tests that account for multiple groups such as 
Tukey). They should be subjected to non-parametric tests such as the Mann Whitney U test.   
 The second key point is that a data transformation can be helpful for analysis and can often 
convert the data to fit a normal distribution. In this context, in pharmacology, we are most familiar 
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with log-normal datasets and recommend log transformation when it can be justified. This is much 
easier to identify than one might imagine: if the s.e.mean increases in size in proportion to the size 
of the mean, this is typically log normal, and the benefits (and indeed the necessity) of log 
transformation are shown in Figure 3. 
 
 
 
 
Figure 3. Individual data points (circles), mean values (x) and s.e.mean values are shown. On the left, owing 
to the large variance in the drug group, a t test identifies the two groups as not significantly different. 
However, closer examination shows this to be a false inference. The individual data values are not equally 
distributed around the arithmetic mean, and an arithmetic s.e.mean is not an appropriate way to summarize 
the distribution (and has therefore been omitted from the figure). If the s.e.mean were to be drawn its size 
would be proportional to the mean (i.e., the larger the mean, the larger the s.e.mean). It is possible to 
analyse the data in the left-hand figure using a non-parametric statistical test (such as a U test), but non-
parametric tests are less powerful than parametric tests and their use can result in false negative findings. In 
the right-hand panel, the same data are log transformed and the Y axis uses the log scale. Here the s.e.mean 
is no longer proportional to the mean, and the values are Gaussian distributed. It is appropriate to show the 
s.e.mean (error bars in the figure). A t test correctly identifies a statistically significant difference between 
groups. This transformation unsettles some investigators as it appears to be a manipulation of data. 
However, in nature, many variables are log normally distributed. Sound (decibels) and acidity (pH) are units 
on a log scale, used because the variable is log Gaussian. In pharmacology the pA2, and even the relationship 
between a response and a drug concentration are log Gaussian. This is why we express agonist and 
antagonist “affinity” values as pKA and pKB, respectively not KA and KB. It should be no surprise that many 
other variables in biology are log-Gaussian (for example the number of ectopic beats occurring in 
experimental myocardial infarction). The key issue here is that authors and peer reviewers should look at 
figures to ensure that data like those in the left-hand part of the figure are not included in a paper – if they 
are the data should be re-analysed.  
 
Group sizes – what is a group size and what is a group? 
 
We have indicated that for BJP n=5 is the minimum acceptable group size for statistical analysis but 
on this issue two other factors warrant consideration. The first is ‘what is a group size’? We allude 
above to a group being comprised of independent samples. But what is an independent sample?  
For BJP, ‘independent’ signifies that the sample represents a bias-free representation of the 
population. Thus, 5 cells from one mouse is not n=5. On the other hand it may be argued that for in 
vivo experimentation datasets derived from 5 mice housed in the same cage should be averaged to 
provide n=1. BJP does not require that data from n=5 mice housed in the same cage should be 
treated as n=1. We will review this position as the field progresses. The second factor is ‘what is a 
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group?’ A group is a collection of independent samples rather than technical replicates. A technical 
replicate is one sample, run/tested/probed again (and again). A single sample of cells, divided into 
three and treated the same way, on the same day, by the same person is a technical triplicate. It is 
n=1. Thus, we expect statistical analysis to be undertaken on independent samples, demonstrably 
independent, and of a minimum group size.  
 
Regarding minimum group sizes and power analysis, we have stated that a good rule of thumb is to 
add 50% to the n determined by power analysis, in order to avoid under powering. This is arbitrary 
guidance. It is based on the fact that power analysis defines the minimum group size to obtain 
significance that is reliable 50% of the time, and thus, that it makes sense to add 50% to the group. 
We may revisit this recommendation in the future. 
 
Experimental outliers 
 
We have debated how to handle outliers within datasets. A recommendation is summarised in the 
guidance list shown above. We begin by defining what we mean.  
 
Outliers may be defined as data values that digress from the central tendency (often also described 
as ‘central location’). There are a range of issues that need to be considered before an investigator 
can decide how to deal with them. First, how does one identify an outlier? With small group sizes 
(n<12) this is difficult or even impossible. It is feasible to define an outlier in a control population, 
but only if the control group has been generated numerous times previously so that a large number 
of control values are available for inspection. 
 
If it is possible to define an outlier (i.e. a value that lies outside a defined range) then the next 
question to address is why a value is an outlier. The reason may be that the value is false, 
contaminated or in some other way incorrect. On the other hand, it may be correct, and the result 
of a natural wide spread of data, or even a bimodal distribution of data. The latter would arise, for 
example, if one were to analyse readouts in a population that expresses a polymorphism, such as 
deficiency in acetylcholinesterase in a small section of the human population. Excluding such outlier 
values/subjects is justified only in an experiment defined to be relevant only to the larger 
population, for instance, in the acetylcholinesterase example, those with typical enzyme activity. It 
is important to know what the explanation is for an outlier, since it is hazardous and potentially 
inappropriate to exclude correct values just because they alter the data distribution. 
 
Genuinely false values should be excluded from a sample, but this must be done using predefined 
criteria. Using a formula based on the standard deviation is one. A number of others are available in 
routinely used statistical packages but their use can be problematic (Leys et al., 2013). Alternatively, 
one may use an arbitrary limit of acceptability (e.g. to exclude animals whose surgery has lowered 
blood pressure to below a value appropriate for testing drug effects especially, in this example, 
effects on blood pressure). This approach is entirely acceptable to BJP, however, the key is to define 
the exclusion criteria beforehand and apply them on blinded data to avoid bias. Exclusion criteria 
should be fully described in the Methods section. 
 
With a novel type of study (i.e. where there are no historical controls and database of records with 
which to consult) it is essential to ensure unbiased quality control, which means undertaking 
preliminary studies in order to allow generation of arbitrary exclusion criteria, keeping in mind that 
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the justification cannot be ‘scientific’, merely pragmatic (to ensure that data can be analysed 
statistically without the need for onerously large group sizes). It is wise to revisit any criteria as new 
data emerge. We encourage authors to present such data within manuscripts. 
 
When the reasons for exclusion of data are impossible to justify, the best solution may be to 
include all data including ‘outliers’ and ensure group sizes are large (increased by 50% from the 
value determined by Power analysis is advisable). When inclusion of outliers is decided to be the 
best option, this may generate non-Gaussian datasets. These can be accommodated by use of 
transformations or non-parametric statistical tests, as discussed above. In summary, outliers should 
be included in a data set unless a predefined and defensible set of exclusion criteria can be 
generated and applied. 
 
Conclusions 
 
Here we have updated and simplified journal requirements for experimental design and analysis. 
The objective is pragmatic – to facilitate manuscript preparation and peer review that is more 
consistent and transparent, and that generates research articles whose data are more likely to be 
reproducible.  
 
The caveat is that there is no panacea since implementation of any process is entirely dependent on 
stakeholders engaging with it. If guidance is too onerous, too detailed or ambiguous, or presented 
as optional (‘best practice’) it will likely fail. If authors ignore the guidance and peer review fails to 
recognise this, we will make no progress. Keeping guidance and the process of its implementation 
simple has a better chance of success than elaboration of complex and detailed guidance on every 
nuance. We will revisit the guidance in 2020, but will also conduct 6 monthly audits, in order to 
monitor its effects, and will introduce new guidance as appropriate.  
 
One issue that we have avoided concerns the meaning of statistical significance. It has been 
suggested that the threshold P that constitutes significance be lowered from the ‘pharmacology 
standard’ of P<0.05 to as low as P<0.001. Others have suggested that ‘significance’ be a forbidden 
word, and that exact P values be presented with the author (or even the reader) offered the 
freedom to make his/her own judgement as to whether to ‘believe’ if an ‘effect’ is ‘real’ or not. BJP 
continues with the policy that authros must define what level of P they define to constitute 
statistical significance within the Methods section of the paper. Authors may select a more 
stringent P threshold that the current norm of P<0.05, but this must not be varied from one part of 
a manuscript to another. We will remain watchful and will assess the evidence and revisit this issue 
as and when the discourse dictates and at the very least in 2020.  
 
Statistical analysis does not guarantee that a finding is necessarily biologically true, and we will 
allow an author the right to argue that a false positive or a false negative finding may have been 
generated. Therefore, some room is needed for expert opinion and the judgement of experience 
(when argued persuasively). In addition, the calculated P value is almost always bigger than it 
seems (‘less significant’) owing to the false discovery rate which is one reason why some 
investigators argue that most (rather than just some) research findings are false (Colquhoun 2014; 
Begley 2013; Begley & Ioannidis 2015).  
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Thus, to summarise, this update describes a modified approach to issues that have arisen from our 
experiences following the publication in 2015 of our design and analysis guidelines. The areas of 
focus have been selected from our internal audits as issues requiring reconsideration and aspects of 
experimentation that we did not consider in the first iteration. We will continue to use this 
approach of internal audit and reappraisal to assess and to ensure that BJP remains at the forefront 
of the agenda encouraging good experimental practice. Our intention is to continue to support the 
Pharmacology community in identifying strategies that support and enable transparency and 
reproducibility. As we stated previously (Curtis et al 2015) some of our guidance is arbitrary, and 
some will change. We will make progress, but it will need clear requirements and vigilance with 
progress won in stages. This is our stage II. 
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